Skip to content

Efficacy and Safety Evaluation of Splendor-X SMART System for hair removal

Efficacy and Safety Evaluation of Splendor-X SMART System for hair removal, Prospective Multi Center Feasibility study, Within-Subject Controlled Treatment in healthy subjects.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON29490
Enrollment
40
Registered
2021-08-04
Start date
2021-10-01
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Excessive hair growth, hirsutism

Interventions

The study includes a total of up to 6 visits: 1 screening visit, 3 treatment visits and 2 follow-up visits.

Sponsors

Lumenis Ltd.
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. All skin types: I-VI 2. male or female 3. Age – 18-50 years of age 4. Having two suitable treatment areas (legs, thighs, back, Chest, axillae, bikini, front of the neck or abdomen) with dark brown or black hair appropriate for hair removal;

Exclusion criteria

Exclusion criteria: 1. Previous hair removal procedures at intended areas 2. Active infections in the treated area; 3. Dysplastic nevi in the treatment area; 4. Significant concurrent skin conditions or any inflammatory skin conditions; 5. Active cold sores, open lacerations or abrasions in the treated area; 6. Chronic or cutaneous viral, fungal, or bacterial diseases; 7. Intense tan, Deep suntan, recent suntan within 2 weeks, sunburn or artificially tanned skin; 8. Current cancer, history of skin cancer or pre-cancerous lesions at the treatment areas;

Design outcomes

Primary

MeasureTime frame
Feasibility of hair removal treatment with the Splendor-X SMART laser platform for hair removal treatment for all skin types.

Secondary

MeasureTime frame
• Percent change of number of hairs before and after 3 treatments with the Splendor-X SMART system as compared to Splendor-X. • Difference between the Splendor-X SMART system and the subjective physician judgment on standard assessments of skin characteristics. • Splendor-X SMART melanin and erythema measurements as compared to MX18 for each treatment.

Contacts

Public ContactAlbert Wolkerstorfer

Amsterdam UMC

a.wolkerstorfer@amsterdamumc.nl+31 20 566 6955

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)